To determine whether NF-κB plays a dominant role in alizarin-mediated anti-pancreatic cancer activity, and given that there was a reduction in IkBα, an NF-κB inhibitor was required for canonical NF-κB activation 21. The gene discussed is NFKB1; the disease is familial pancreatic carcinoma.